Top 20 of Glioma

Article title # Publications/# Citations

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response.

2006: SBao; DDBigner; MWDewhirst; YHao; ABHjelmeland; REMcLendon; JNRich; QShi; QWu;

813

IDH1 and IDH2 mutations in gliomas.

2009: IBatinic-Haberle; DDBigner; AFriedman; HFriedman; JHerndon; GJin; SJones; KWKinzler; ... IKos; RMcLendon; DWParsons; BARasheed; DReardon; GJRiggins; VEVelculescu; BVogelstein; HYan; WYuan;

503

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

2006: KAldape; RChen; HColman; BGFeuerstein; WFForrest; SKharbanda; AMisra; ZModrusan; ... JMNigro; HSPhillips; RHSoriano; LSoroceanu; PMWilliams; TDWu;

494

Malignant gliomas in adults.

2008: SKesari; PYWen;

422

Response criteria for phase II studies of supratentorial malignant glioma.

1990: JGCairncross; TLCascino; DRMacdonald; SCSchold;

340

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

2009: BDBennett; MABittinger; LCCantley; LDang; EMDriggers; VRFantin; SGross; HGJang; ... SJin; MCKeenan; LMLiau; KMMarks; RMPrins; JDRabinowitz; SMSu; CBThompson; MGVander Heiden; PSWard; DWWhite; KEYen;

334

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma.

2007: SAlexander; JBarretina; RBeroukhim; TFCloughesy; RMDeBiasi; FDemichelis; JDu; LAGarraway; ... GGetz; TAGolub; CHatton; THsueh; JHHuang; TKau; ESLander; JCLee; LLiau; DLinhart; IKMellinghoff; MMeyerson; PSMischel; SFNelson; LNghiemphu; SPerner; JPrensner; MARubin; WRSellers; KShah; HSoto; RKThomas; IVivanco;

292

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

1992: GBreier; KHPlate; WRisau; HAWeich;

260

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

1999: CRAlexander; PBoland; DCompton; JHolash; PCMaisonpierre; SJWiegand; GDYancopoulos; DZagzag;

249

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.

2011: SFrye; KLGuan; SIto; WQJiang; SHKim; QYLei; JLiu; LXLiu; ... YLiu; BWang; PWang; PWang; MTXiao; YXiong; WXu; YHXu; CYang; HYang; YYang; JYZhang; YZhang; SMZhao;

229

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

2000: EAndion; SBBaylin; MEsteller; JGarcia-Foncillas; SNGoodman; JGHerman; OFHidalgo; VVanaclocha;

216

5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers.

1995: SBBaylin; PCBurger; EGabrielson; JGHerman; DJLee; LMao; AMerlo; DSidransky;

211

Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

2010: MCChamberlain; SMChang; TFCloughesy; JDegroot; EGalanis; MRGilbert; KRLamborn; ABLassman; ... DRMacdonald; TMikkelsen; DAReardon; AGSorensen; RStupp; CTsien; MJvan den Bent; MAVogelbaum; PYWen; WWick; ETWong;

209

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

2006: SBao; DDBigner; YHao; ABHjelmeland; ZLi; REMcLendon; JNRich; SSathornsumetee; QShi; QWu;

203

Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

1987: EChen; LCoussens; TJDull; UFrancke; WJKuang; SMunemitsu; JSchlessinger; AUllrich; TYang-Feng; YYarden;

200

The transcriptional network for mesenchymal transformation of brain tumours.

2009: KAldape; MJÁlvarez; SLAnne; RJBollo; ACalifano; MSCarro; HColman; FDoetsch; ... AIavarone; ALasorella; WKLim; EYSnyder; EPSulman; XZhao;

198

Malignant glioma: genetics and biology of a grave matter.

2001: RMBachoo; WKCavenee; RADepinho; FBFurnari; DNLouis; EAMaher; DHRowitch;

196

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

2004: MFBooth; SSChae; EDi Tomaso; DFukumura; IGarkavtsev; DJHicklin; RKJain; SVKozin; ... LLMunn; RTTong; FWinkler; LXu;

189

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

2007: DDBigner; ADesjardins; JMDowell; AHFriedman; HSFriedman; SGururangan; JEHerndon; JAQuinn; ... DAReardon; JNRich; SSathornsumetee; JJVredenburgh; MWagner;

185

HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity.

2006: VClément; Nde Tribolet; IRadovanovic; ARuiz i Altaba; PSánchez;

180